Alkem Laboratories has officially confirmed a substantial increase in its planned investment for a new greenfield formulations manufacturing plant in Ujjain, Madhya Pradesh. The pharmaceutical company's board approved the enhanced capital allocation on April 2, 2026, nearly doubling the original investment commitment as disclosed under Regulation 30 of SEBI LODR Regulations.

Investment Enhancement Details

The board's decision represents a significant scaling up of the company's manufacturing expansion plans. The revised investment framework demonstrates Alkem Laboratories' confidence in the project's potential and its commitment to strengthening production capabilities.

Strategic Manufacturing Expansion

The greenfield facility in Ujjain represents a strategic addition to Alkem Laboratories' manufacturing network. The formulations plant will enhance the company's production capacity and operational flexibility in the pharmaceutical sector. The company had earlier received an allotment letter dated March 18, 2026, from DMIC Vikram Udyogpuri Limited for the 30-acre land parcel.

Regulatory Compliance and Timeline

The investment approval follows proper regulatory disclosure protocols under SEBI LODR Regulations. The board had initially approved an investment of up to ₹533 crores in March 2026, which has now been enhanced to ₹1,036 crores. The phased implementation approach allows for controlled deployment of capital and systematic facility development.

The enhanced investment commitment reflects Alkem Laboratories' strategic focus on expanding its manufacturing infrastructure and strengthening its position in the pharmaceutical formulations market.

Alkem laboratories has announced significant changes in its senior management structure, filing mandatory disclosures with stock exchanges under regulatory compliance requirements. The pharmaceutical company reported two key personnel transitions affecting its leadership team.

Senior Management Transitions

The company disclosed two distinct changes in its senior management positions through official communication dated March 31, 2026. These changes were reported pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance Details

The disclosures were made in accordance with SEBI Master Circular bearing reference number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company filed the required information under Schedule III, Part A of the SEBI LODR Regulations.

Key aspects of the regulatory filing include:

• Superannuation Process: Mr. Ravinder Chaklam's departure from senior management was due to superannuation
• Subsidiary Transfer: Mr. Mukesh Tiwari's appointment to the wholly owned subsidiary resulted in cessation from parent company senior management
• Compliance Timeline: The company acknowledged unintentional delay due to inadvertent oversight

Corporate Communication

The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, and communicated to both BSE Limited and National Stock Exchange of India Limited. The information has been made available on the company's official website at www.alkemlabs.com .

The company maintains its registered office at ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai, and continues its operations under CIN: L00305MH1973PLC174201. These management changes represent routine corporate governance activities as part of the company's ongoing organizational structure management.